Amgen and Astellas Announce Japan Alliance
News May 30, 2013
The alliance leverages the complementary capabilities of both companies through an innovative business model that combines Amgen’s pipeline candidates with Astellas’ deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan.
The first element of the alliance is a long-term collaboration between the two companies that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline medicines. The five medicines, which include four biologics and one small molecule, are focused on the treatment of cardiovascular and bone diseases and cancer. The pipeline medicines range from early to late stages of development in Japan, with the first potential commercial launch expected as early as 2016.
The second element of the alliance is the establishment of a Tokyo-based joint venture company through which the companies will work together to enable Amgen to rapidly build on-the-ground capabilities in Japan. The joint venture will operate under the name Amgen Astellas BioPharma KK and will be led by Eiichi Takahashi, who will serve as general manager. Additional management roles will be appointed by Amgen and Astellas. The joint venture will be staffed by seconded employees from Astellas, transferred employees from Amgen and newly hired employees. It is expected that the joint venture will start operations on Oct. 1, 2013, and will become a wholly owned Amgen affiliate as soon as 2020 with the long-term collaboration continuing.
“Through this alliance, Amgen will work closely with Astellas to leverage its extensive knowledge of the local market,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “With Astellas’ strong capabilities and excellent reputation, this alliance will help accelerate development and commercialization of Amgen medicines for patients in Japan. This alliance reflects our long-term commitment to the Japan market and is an important step in our global expansion efforts."
“We look forward to entering this alliance with Amgen and believe it will strengthen our pipeline to address unmet medical needs, as well as enable us to obtain growth drivers,” said Yoshihiko Hatanaka, president and CEO of Astellas. “We will work closely with Amgen to build the joint venture, which will provide innovative medicines to patients in Japan.”
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Exploring Challenges in the Synthesis of Pharmaceutical DrugsNews
This summer, Wendell and Loretta Hess Professor of Chemistry Ram Mohan will travel to India and Hong Kong to deliver a series of post-graduate workshops on advanced concepts in organic synthesis.
His workshop “Advanced Concepts in the Synthesis of Pharmaceutical Drugs” at the Indian Institute of Technology Indore will explore the unique, real-world challenges in the pharmaceutical industry to synthesize drugs that are both commercially viable and eco-friendly.
Modern Alchemists are Making Chemistry GreenerNews
Ancient alchemists tried to turn lead and other common metals into gold and platinum. Modern chemists in Paul Chirik’s lab at Princeton are transforming reactions that have depended on environmentally unfriendly precious metals, finding cheaper and greener alternatives to replace platinum, rhodium and other precious metals in drug production and other reactions.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018